SillaJen : China’s FDA Oks To Commence Phase 3 Trial For Oncolytic Immunotherapy – Nasdaq
|
SillaJen : China's FDA Oks To Commence Phase 3 Trial For Oncolytic Immunotherapy
Nasdaq (RTTNews.com) – SillaJen, Inc. and Lee's Pharmaceutical Holdings Ltd. announced approval by the China Food and Drug Administration to conduct a Phase 3 clinical trial for advanced liver cancer using its oncolytic immunotherapy called Pexa-Vec (formerly … |
